Terry Smith's position in Catalyst Pharmaceuticals is currently worth $56.5M. That's 0.25% of their equity portfolio (32nd largest holding). The investor owns 2.21% of the outstanding Catalyst Pharmaceuticals stock. The investor's estimated purchase price is $61.6M, resulting in a loss of 8.4%.